ExodusPoint Capital Management’s ImmunityBio IBRX Stock Holding History
Bought
Maintained
Sold
Other funds holding IBRX
ExodusPoint Capital Management's IBRX Position: Q3 2026 in Review
ExodusPoint Capital Management increased its ImmunityBio (IBRX) stake by 80% in Q3 2026, buying an estimated $1.23M and bringing the position to 347,388 shares worth $3.28M. The position accounts for 0.02% of the portfolio, ranked #705.
ExodusPoint Capital Management first reported a position in IBRX in Q4 2019 and has held it in 13 quarters since. 407 funds tracked by Wall St. Rank hold IBRX as of Q3 2026.
- ExodusPoint Capital Management held 347,388 shares of ImmunityBio worth $3.28M as of Q3 2026.
- ExodusPoint Capital Management bought 154,048 ImmunityBio shares in Q3 2026, an estimated $1.23M.
- ImmunityBio made up 0.02% of ExodusPoint Capital Management's portfolio in Q3 2026, its #705 holding.
- ExodusPoint Capital Management first reported a position in ImmunityBio in Q4 2019 and has held it in 13 quarters since.
- 407 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2026.
Based on ExodusPoint Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.